These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Allosteric modulators of the α4β2 subtype of neuronal nicotinic acetylcholine receptors. Pandya A; Yakel JL Biochem Pharmacol; 2011 Oct; 82(8):952-8. PubMed ID: 21596025 [TBL] [Abstract][Full Text] [Related]
10. Discovery of an intrasubunit nicotinic acetylcholine receptor-binding site for the positive allosteric modulator Br-PBTC. Norleans J; Wang J; Kuryatov A; Leffler A; Doebelin C; Kamenecka TM; Lindstrom J J Biol Chem; 2019 Aug; 294(32):12132-12145. PubMed ID: 31221718 [TBL] [Abstract][Full Text] [Related]
11. Advances in the In vitro and In vivo pharmacology of Alpha4beta2 nicotinic receptor positive allosteric modulators. Wilkerson JL; Deba F; Crowley ML; Hamouda AK; McMahon LR Neuropharmacology; 2020 May; 168():108008. PubMed ID: 32113032 [TBL] [Abstract][Full Text] [Related]
12. The nicotinic acetylcholine receptor: a typical 'allosteric machine'. Changeux JP Philos Trans R Soc Lond B Biol Sci; 2018 Jun; 373(1749):. PubMed ID: 29735728 [TBL] [Abstract][Full Text] [Related]
13. Allosteric proteins after thirty years: the binding and state functions of the neuronal alpha 7 nicotinic acetylcholine receptors. Edelstein SJ; Changeux JP Experientia; 1996 Dec; 52(12):1083-90. PubMed ID: 8988250 [TBL] [Abstract][Full Text] [Related]
14. Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations. Williams DK; Wang J; Papke RL Biochem Pharmacol; 2011 Oct; 82(8):915-30. PubMed ID: 21575610 [TBL] [Abstract][Full Text] [Related]
15. Nicotinic receptor pharmacology in silico: Insights and challenges. Gulsevin A Neuropharmacology; 2020 Oct; 177():108257. PubMed ID: 32738311 [TBL] [Abstract][Full Text] [Related]
16. Identification of a negative allosteric site on human α4β2 and α3β4 neuronal nicotinic acetylcholine receptors. Pavlovicz RE; Henderson BJ; Bonnell AB; Boyd RT; McKay DB; Li C PLoS One; 2011; 6(9):e24949. PubMed ID: 21949802 [TBL] [Abstract][Full Text] [Related]
17. Binding properties of agonists and antagonists to distinct allosteric states of the nicotinic acetylcholine receptor are incompatible with a concerted model. Krauss M; Korr D; Herrmann A; Hucho F J Biol Chem; 2000 Sep; 275(39):30196-201. PubMed ID: 10900197 [TBL] [Abstract][Full Text] [Related]
18. Positive allosteric modulation of the alpha7 nicotinic acetylcholine receptor: ligand interactions with distinct binding sites and evidence for a prominent role of the M2-M3 segment. Bertrand D; Bertrand S; Cassar S; Gubbins E; Li J; Gopalakrishnan M Mol Pharmacol; 2008 Nov; 74(5):1407-16. PubMed ID: 18678621 [TBL] [Abstract][Full Text] [Related]
19. Disruption of the Na+ ion binding site as a mechanism for positive allosteric modulation of the mu-opioid receptor. Livingston KE; Traynor JR Proc Natl Acad Sci U S A; 2014 Dec; 111(51):18369-74. PubMed ID: 25489080 [TBL] [Abstract][Full Text] [Related]
20. Allosteric modulators of α4β2 nicotinic acetylcholine receptors: a new direction for antidepressant drug discovery. Mantione E; Micheloni S; Alcaino C; New K; Mazzaferro S; Bermudez I Future Med Chem; 2012 Nov; 4(17):2217-30. PubMed ID: 23190109 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]